P1101 (Ropeginterferon alfa-2b)

DRUG3 trials

Sponsors

National Taiwan University Hospital, PharmaEssentia Japan K.K.

Conditions

COVID-19Hepatocellular CarcinomaPolycythemia Vera (PV)

Phase 1

P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma

National Taiwan University HospitalHepatocellular Carcinoma

Start: 2019-02-12End: 2023-07-31Target: 72Updated: 2022-01-27

Phase 3

Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

RecruitingNCT04655092

PharmaEssentia Japan K.K.Polycythemia Vera (PV)

Start: 2021-01-19End: 2026-06-30Target: 67Updated: 2024-11-08

Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Moderate COVID19.

CompletedNCT05770466

National Taiwan University HospitalCOVID-19

Start: 2022-04-01End: 2023-01-11Updated: 2024-04-16